Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: A 16-week, randomized, double-blind, placebo-controlled phase III trial

Diabetes, Obesity and Metabolism

Volumn 17, Issue 3, 2015, Pages 309-312

  Kim, M K ^a   Rhee, E J ^b   Han, K A ^c   Woo, A C ^d   Lee, M K ^b   Ku, B J ^e   Chung, C H ^f   Kim, K A ^g   Lee, H W ^h   Park, I B ⁱ   Park, J Y ^j   Chul Jang, H C ^k   Park, K S ^l   Jang, W I ^m   Cha, B Y ^a  

^a The Catholic University of Korea   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Eulji General Hospital   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Chungnam National University   (South Korea)

^f Yonsei University Wonju College of Medicine   (South Korea)

^g Dongguk University Ilsan Hospital   (South Korea)

^h Yeungnam University College of Medicine   (South Korea)

ⁱ Gachon University College of Medicine   (South Korea)

^j University of Ulsan College of Medicine   (South Korea)

^k Seoul National University Bundang Hospital   (South Korea)

^l Seoul National University College of Medicine   (South Korea)

^m Handok Pharmaceutical Inc   (South Korea)

more..

Author keywords

DPP 4 inhibitors; Korean; Metformin; Teneligliptin

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; TENELIGLIPTIN; 3-(4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YLCARBONYL)THIAZOLIDINE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ARTICLE; BODY WEIGHT; CELL FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; ETHNOLOGY; PROCEDURES; SOUTH KOREA;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FASTING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PYRAZOLES; REPUBLIC OF KOREA; THIAZOLIDINES;

EID: 84922025125     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12424     Document Type: Article

References (12)

1. Goda M, Kadowaki T. Teneligliptin for the treatment of type 2 diabetes. Drugs Today (Barc) 2013; 49: 615-629.
2. Nabeno M, Akahoshi F, Kishida H et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 2013; 434: 191-196.
3. Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2012; 14: 1040-1046.
4. Scott R, Loeys T, Davies MJ, Engel SS, Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 959-969.
5. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.
6. Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul) 2013; 28: 262-274.
7. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013; 56: 696-708.
8. Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2013; 4: 576-584.
9. Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab 2014; 16: 418-425.
10. Liu Y, Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab 2014; 16: 111-117.
11. Yoon KH, Shin JA, Kwon HS et al. Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. Diabetes Metab J 2011; 35: 26-33.
12. Filippatos TD, Athyros VG, Elisaf MS. The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors. Expert Opin Drug Metab Toxicol 2014; 10: 787-812.